Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the ...

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused ...

The Best SSDs and Storage - Late 2025 Update

To expand storage on a Steam Deck, Asus ROG Ally, or Surface Pro, you're locked into a single form factor: the short 2230 M.2 drive. Updated in 2024 with Phison's E27T controller, the Corsair MP600 ...

The tablet that made me put away my iPad and Kindle has a worthy successor - and it's on sale

The TCL Nxtpaper 11 Plus is a well-rounded Android tablet that delivers reliable everyday performance at an accessible price.